Quark Pharmaceutical Showcases Commitment to Nuclear Medicine at China (International) Nuclear Technology Application Industry Development Forum

On June 23, the China (International) Nuclear Technology Application Industry Development Forum, hosted by the China Isotope and Radiation Industry Association, opened in Beijing. As one of the co-organizers, Quark Pharma made its appearance at the forum. Representing an emerging force among nuclear medicine CROs in China, Quark Pharma fully demonstrated its determination to accelerate its strategic deployment in nuclear medicine and drive the high-quality development of the sector in China, guided by its unique service philosophy of "Accompanying Growth, Achieving Client Success."

Themed "Nuclear Technology for a Better Life," this forum will span three days. Throughout the conference, over 300 experts and scholars from domestic and international nuclear technology application fields, along with dozens of representative enterprises in the sector, will utilize formats such as keynote reports and roundtable discussions to extensively explore cutting-edge developments in the nuclear medicine industry, examine innovative corporate development models, and establish collaborative communication mechanisms and win-win partnerships among all participating parties.

Quark Pharma possesses extensive service experience and robust capabilities in the field of diagnostic and therapeutic radiopharmaceuticals. Yuan Dawei, Chairman of Quark Pharma, stated that nuclear medicine diagnostics and therapy represent a key strategic priority for the company. By actively promoting the clinical application of nuclear medicine and enhancing its nuclear medicine CRO service capabilities, Quark Pharma is committed to contributing its expertise and strength to the high-quality development of China's nuclear medicine sector.

In recent years, Quark Pharma has actively practiced its service philosophy of “Accompanying Growth·Achieving Client Success,” consistently delivering high-quality services, earning client trust through long-term dedication, and continuously enhancing its service capabilities. The company has established distinct service advantages in nuclear medicine, reproductive medicine, cell therapy, and modified new drugs, forming a robust CRO service system and strong service capabilities.

From the 24th to the 25th, Quark Pharma attended the main venue of the “Press Conference and Forum on the Medium- and Long-Term Development Plan for Medical Isotopes,” as well as the parallel sessions and roundtable discussions themed “Radiation Technology Empowering a Healthy China” and “Nuclear Technology (Proton and Heavy Ion) Empowering a New Life for Cancer Patients.” Together with attending experts, the company contributed its expertise and efforts to the robust development of China’s nuclear technology application industry.

Responsible Editor: Bai Ji